Russia’s mRNA cancer vaccine, tailored for personalized treatment, promises to reduce tumor size by up to 80%, with free distribution set for 2025.
In a groundbreaking development, Russia’s Ministry of Health has announced the creation of a pioneering mRNA cancer vaccine, designed to reduce tumor size by 75-80% and slow tumor progression. The vaccine will be available free of charge to cancer patients starting in early 2025, marking a significant advancement in personalized cancer treatment.
Personalized Cancer Treatment Breakthrough
The vaccine, intended for therapeutic use, is tailored to target individual cancer types and genetic markers. Andrey Kaprin, head of the Radiology Medical Research Center, highlighted the innovative approach, emphasizing that this is not a universal solution but a personalized treatment designed specifically for diagnosed patients.
Alexander Gintsburg, director of the Gamaleya National Research Center, elaborated on its precision:
“This is not a universal vaccine. It is a personalized vaccine, not only for each type of cancer but also for each respective kind of cancer patient.”
How the Vaccine Works
Utilizing mRNA technology, the vaccine instructs the body’s cells to produce proteins that mimic those found in cancer cells, prompting the immune system to identify and attack malignant cells. Cytotoxic lymphocytes, the immune system’s specialized cells, then target and destroy the tumors. Gintsburg explained:
“This drug or vaccine directs the patient’s immune system against malignant cells because it carries changes characteristic at the genetic level of tumors.”
The vaccine’s development has also incorporated cutting-edge artificial intelligence (AI) to expedite the process. With the involvement of the Ivannikov Institute, researchers aim to use AI algorithms to customize vaccines in less than an hour. Gintsburg noted:
“These procedures should take about half an hour to an hour, significantly speeding up the creation of personalized solutions for each patient.”
The first phase of development will target melanoma, one of the deadliest forms of skin cancer. Early trials in mouse models have shown encouraging results, laying the groundwork for human clinical trials. Researchers aim to expand the vaccine’s application to other cancer types based on its success.
Join our Channel...